Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 481 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA approves Mylan Zolmitriptan ANDA

The generic equivalent of IPR Pharmaceuticals’ Zomig tablets is indicated for the acute treatment of migraine with or without aura in adults. Mylan commenced the product shipment. The

Hitachi to market Nanosphere products in Japan

With the agreement, Hitachi High-Technologies will gain exclusive rights to market Nanosphere products in Japan. The two companies also plan to collaborate on assay and platform development. Hitachi